Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CTSG | P08311 | 1/20 | 0.38 |
| ▸ | CMA1 | P23946 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.37 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27233706 | 0.86 | MMP2 (0.44) | L3MBTL1MMP2CA1CA2MAPT | |
| SCHEMBL25979813 | 0.75 | MMP2 (0.41) | MMP2CA1CA2MAPTRECQL | |
| SCHEMBL3213248 | 0.74 | MMP2 (0.46) | L3MBTL1MMP2CA1CA2MAPT | |
| SCHEMBL15230721 | 0.70 | CA1 (0.41) | L3MBTL1MMP2CA1CA2MAPT | |
| SCHEMBL26980233 | 0.70 | PKM (0.42) | L3MBTL1MMP2CA1CA2MAPT | |
| SCHEMBL15230723 | 0.70 | CA1 (0.41) | L3MBTL1MMP2CA1CA2MAPT | |
| SCHEMBL10854578 | 0.70 | MMP2 (0.42) | L3MBTL1MMP2CA1CA2MAPT | |
| SCHEMBL30977375 | 0.70 | MMP2 (0.47) | L3MBTL1MMP2CA1CA2MAPT | |
| SCHEMBL20780052 | 0.69 | PKM (0.46) | L3MBTL1MMP2CA1CA2MAPT | |
| SCHEMBL7683230 | 0.69 | CA1 (0.50) | L3MBTL1MMP2CA1CA2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11939340-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2024-03-26 | — | — | US | disclosed |
| US-20230257394-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2023-08-17 | — | — | US | disclosed |
| US-20230234964-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11939340-B2 | CDK inhibitors and their use as pharmaceuticals | CDK6, CDK1, CDK3 | L3MBTL1 3688/4885MMP2 3156/4885CA1 4014/4885 |
| US-20230234964-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK1, CDK3 | L3MBTL1 3688/4885MMP2 3156/4885CA1 4014/4885 |
| US-20230257394-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK1, CDK3 | L3MBTL1 3688/4885MMP2 3156/4885CA1 4014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.